<DOC>
	<DOCNO>NCT00956098</DOCNO>
	<brief_summary>This study investigate effectiveness safety oltipraz therapy treat patient cirrhosis induce chronic hepatitis type B C .</brief_summary>
	<brief_title>Efficacy Safety Oltipraz Patients With Liver Fibrosis Cirrhosis</brief_title>
	<detailed_description>Oltipraz [ 5- ( 2-pyrazinyl ) -4-methyl-1,2-dithiol-3-thione ] extensively study cancer chemopreventive agent . Comprehensive mechanistic phase IIa study support notion oltipraz exerts chemopreventive effect , support Phase IIa human clinical study oltipraz cancer chemoprevention , conduct Qidong , China . Hepatic stellate cell cause synthesis large quantity extracellular matrix . Transforming growth factor beta1 ( TGF-beta1 ) , key fibrogenic mediator fibrogenesis injury deposition extracellular matrix inhibition collagenase activity liver , associate regulation cell growth differentiation cause synthesis extracellular matrix protein cellular receptor matrix protein . Previously , report effectiveness oltipraz regeneration cirrhotic liver , include reduction intensity liver fibrotic cirrhotic nodule , elimination accumulate extracellular matrix , regeneration cirrhotic liver animal model . Oltipraz completely resolve fibrosis cirrhotic liver , thereby improve viability . TGF-beta1 signaling play important role liver fibrogenesis cirrhosis evidence receptor knockout experiment . No therapeutic agent active interrupt TGF-beta1 signal available , propose C/EBP serve molecular target treatment liver cirrhosis .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Oltipraz</mesh_term>
	<criteria>patient fibrosis cirrhosis induce chronic hepatitis type B C patient HbsAg , AntiHCV HCV RNA positive treatment antiviral agent , immunosuppressant , glucocorticoid , within 6 month biphenyl dimethyl dicarboxylate one month treatment investigational drug ( except CJ11555PK CJOPZ201PK ) within one month ChildPugh class C , Use mean daily dose 80 g alcohol one month , enzyme inducer inhibitor , drug abuse might affect study know hypersensitivity oltipraz structurally related compound ascites , hemorrhage varicoses , uncompensated LC history hepatic encephalopathy within 6 month hepatocellular carcinoma ( rise serum level Î±fetoprotein suspicious focus hepatic ultrasonography screen ) , liver transplantation pregnancy lactation , unwillingness contraception study period serious concurrent illness ( e.g. , severe hemorrhagic GI , renal , pulmonary , neurological , cardiovascular ( CHF class III ; history MI within past 6 month ) disease , cancer , autoimmunity psychological disease ) patient inappropriate unwillingness clinical study judge participate clinician bilirubin content great 2.0 mg/dL , prothrombin time longer 4 sec , serum albumin 2.5 g/dL</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2009</verification_date>
</DOC>